Pharma Equity Group A/S (PEGc)

Overview

Pharma Equity Group A/S, via its subsidiary Reponex Pharmaceuticals A/S, is a clinical-stage biopharmaceutical company based in Horsholm, Denmark. Established in 2002, the company focuses on developing innovative treatments for diseases that pose significant patient and social challenges, especially where existing therapies are inadequate or require enhancements. The mission of Pharma Equity Group is to address unmet medical needs through advanced pharmaceutical research and development, striving to improve patient outcomes and overall healthcare quality.

Products and Services

• RNX-011

  This product is being developed for the treatment of bacterial peritonitis, a serious infection that can occur in patients with liver disease or those undergoing dialysis. RNX-011 aims to provide an effective therapeutic option that improves recovery times and patient outcomes.

• RNX-021, RNX-022, and RNX-023

  These three products are under development to address the treatment of chronic skin ulcers. Chronic skin ulcers represent a significant health concern as they can lead to severe complications such as infections and amputations. These products seek to facilitate healing and offer a better quality of life for patients suffering from these conditions.

• RNX-041

  This therapeutic candidate targets inflammatory bowel diseases, specifically Crohn's disease and pouchitis. RNX-041 is designed to alleviate symptoms, reduce inflammation, and ultimately improve the lifestyle of patients dealing with these chronic gastrointestinal disorders.

• RNX-051

  In development for the treatment of colorectal cancer and colon adenoma, RNX-051 is a critical candidate in the oncology space aimed at improving therapeutic outcomes. This product is currently in Phase II clinical trials, emphasizing the company’s commitment to advancing cancer treatment through innovative solutions.